By Ishaq Dabai
Ma’aikatan farar hula, da suka kasa yin allurar rigakafi, basu da wani zaɓi face su biya kudi Naira 79,000 a kowane mako don gwajin cutar COVID-19 a dakunan gwaje-gwaje na masu zaman kansu.
An samo farashin gwajin daga tashar biyan kuɗi na Cibiyar Kula da Cututtuka ta Najeriya ranar Lahadi.
Jaridar Dimokuradiyya ta rawaito cewa Gwamnatin Tarayya, ta hannun Kwamitin Shugaban Kasa kan cutar COVID-19, a makon daya gabata tace za ta hana ma’aikatan farar hula marasa rigakafin alluran shiga ofisoshin su daga ranar 1 ga watan Disamba, 2021.
Babban Daraktan Hukumar Bunkasa Kiwon Lafiya na Matakin Farko, Faisal Shuaib, a ranar 31 ga watan Agusta, 2021 shine ya bayyana hakan inda kuma yayi nuni da yiwuwar saka takunkumi ga wadanda suka ki daukar allurar saboda zasu jefa wasu cikin hadari.
Shima a nasa bangaren Shugaban kwamitin na PSC, Boss Mustapha, a ranar 3 ga watan Satumba lokacin da yake ganawa da kwamishinonin lafiya a Abuja yace alluran rigakafin za su zama tilas ga ma’aikatan gwamnati.tuni dai, a ranar 13 ga watan Oktoba 2021, kwamitin yaci gaba da aiwatar da umurnin sa kan allurar rigakafin cutar COVID-19 ga ma’aikatan gwamnati.
“Tun daga ranar 1 ga watan Disamba 2021, za a buƙaci ma’aikatan Gwamnatin Tarayya su nuna shaidar rigakafin COVID-19 ko gabatar da sakamakon gwajin COVID-19 PCR mara kyau da aka yi cikin awanni 72 don samun damar shiga ofisoshin su a duk wurare a cikin Najeriya domin yin ayyuka, ”in ji Mustapha.Dangane da ƙididdigar hukumar NCDC, gwajin PCR yana biyan Naira 39,500, don haka ɗaukar gwajin sau biyu a mako zai kashe N79,000.
Yayin da ASCN ta zargi Gwamnatin Tarayya da kokarin haifar da tashin hankali tsakanin ma’aikatan gwamnati, JOHESU tace gwamnati ba ta da hankali.Ya zuwa 16 ga watan Oktoba 2021, Najeriya ta bada rahoton mutane 209,158 da aka tabbatar sun kamu da COVID-19, yayin da aka sallami marasa lafiya 197,089, 9,265 masu aiki kuma 2,804 sun rasa rayukansu.
Kashi 2.3 cikin 100 ne kawai na mutanen da aka yiwa allurar rigakafin duk da samun alluran rigakafi a cikin ƙasar tare da wani rukunin allurar AstraZeneca (Oxford) da ke ƙarewa zuwa ƙarshen Oktoba.